Stockreport

What Viridian Therapeutics (VRDN)'s 2025 Losses and Thyroid Eye Disease Milestones Mean For Shareholders [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF The company also highlighted progress for thyroid eye disease programs, including a June 30, 2026 PDUFA date for veligrotug and ongoing Phase 3 trials for elegrobart. [Read more]